Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy.

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with unknown causes and limited effective treatments.
• Evidence suggests immune system alterations in both humans and animal models of ASD, highlighting immune imbalance as a potential therapeutic target.
• Current therapeutic options for ASD are limited, necessitating exploration of novel treatment pathways.

Purpose of the Study:

• To review existing research on anti-inflammatory and immunomodulatory therapies for ASD.
• To categorize ASD therapies based on their primary mechanisms of action, distinguishing between direct immunomodulatory agents and those with secondary immunomodulatory effects.
• To identify gaps in current research and suggest future directions for ASD treatment development.

Main Methods:

• Systematic review and classification of studies on ASD therapies.
• Grouping therapies into two categories: those with primary anti-inflammatory/immunomodulatory actions and those with secondary immunomodulatory effects.
• Analysis of various data acquisition methodologies used in the reviewed studies.

Main Results:

• Group 1 therapies with primary anti-inflammatory/immunomodulatory actions include sulforaphane, celecoxib, lenalidomide, pentoxifylline, spironolactone, luteolin, corticosteroids, immunoglobulins, cell therapy, dialyzable lymphocyte extracts, minocycline, and pioglitazone.
• Group 2 therapies with initially non-immunomodulatory but later discovered immunomodulatory capacities include risperidone, vitamin D, omega-3 fatty acids, Ginkgo biloba, L-carnosine, N-acetylcysteine, and microbiome restoration.
• The reviewed studies employed diverse methodologies, indicating a need for standardization.

Conclusions:

• Immune system modulation presents a promising avenue for novel ASD therapies.
• There is a critical need for more randomized, placebo-controlled studies with larger participant numbers to validate the efficacy of these therapies.
• The development and utilization of biomarkers are essential for refining personalized treatment strategies for individuals with ASD.